

ESPS Peer-review Report**Name of Journal:** World Journal of Clinical Oncology**ESPS Manuscript NO:** 8655**Title:** THE ASSOCIATION OF APOPTOTIC GENE SURVIVIN AND ITS SPLICE VARIANTS WITH THE PROGNOSIS AND TREATMENT OF BREAST CANCER**Reviewer code:** 00653372**Science editor:** Ling-Ling Wen**Date sent for review:** 2014-01-02 15:18**Date reviewed:** 2014-01-14 03:57

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The manuscript by Pavlidou et al. describes the current understanding of survivin and its splice variants. The manuscript is well written and provides a detailed review of the topics in breast cancer.

ESPS Peer-review Report
Name of Journal: World Journal of Clinical Oncology

ESPS Manuscript NO: 8655

Title: THE ASSOCIATION OF APOPTOTIC GENE SURVIVIN AND ITS SPLICE VARIANTS WITH THE PROGNOSIS AND TREATMENT OF BREAST CANCER

Reviewer code: 02884529

Science editor: Ling-Ling Wen

Date sent for review: 2014-01-02 15:18

Date reviewed: 2014-03-07 18:19

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This is a very comprehensive review about the use of survivin and its isoforms as putative biomarker in breast cancer. Overall, the paper is very well written, but some mistakes should be corrected. 1. To uniform the words "tumor" or "tumour", "downregulation" or "down-regulation", "over expression" or "over-expression". 2. The abbreviation of doxorubicin should be put on page 17 and not on page 18. 3. Page 4, last line: it should be put a "comma" after survivin and the "is" should be removed. 4. Page 7, line 7: the sentence should have a full stop at the end. 5. Page 14: the last sentence "The sequestration in particular....envisaged" it is not necessary and should be removed. 6. Page 15, line 15: the word "cause" should be removed. 7. Page 22, line 11: the word "make" should be replaced by "become". 8. Page 23, line 1: the word "that" appear in duplicated.